Gastroparesis Market Analysis Highlights Growth To $9.29 Billion By 2030 At 5.5% CAGR

The gastroparesis market is poised for significant advancement over the coming years, driven by a blend of technological innovation and growing clinical awareness. This evolving sector is attracting attention due to its potential to address a range of digestive health challenges through novel therapies and improved treatment options. Below is a detailed exploration of the market's size, key players, emerging trends, and segmentation.

Projected Growth Trajectory of the Gastroparesis Market
Forecasts indicate the gastroparesis market will expand to reach a valuation of $9.29 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.5%. This upward trend is propelled by several factors, including advancements in implantable stimulation devices, the rise of outpatient care models, an increasing number of diabetic patients, heightened demand for therapies targeting specific symptoms, and enhanced clinical understanding of the condition. Among the prominent trends shaping the market are the broader use of prokinetic drugs, greater adoption of gastric electrical stimulation technologies, intensified emphasis on dietary and lifestyle interventions, the rise of minimally invasive surgery, and better diagnostic approaches specifically for diabetic gastroparesis.

The gastroparesis market size has grown strongly in recent years. It will grow from $7.15 billion in 2025 to $7.52 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to diabetes-related gastric disorders, use of antiemetic medications, hospital-based gi care, dietary management approaches, availability of diagnostic imaging.

Download a free sample of the gastroparesis market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12189&type=smp&utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Key Market Players Driving Innovation and Expansion
The gastroparesis landscape features a variety of influential companies committed to developing effective treatments. Major participants include Pfizer Inc., GlaxoSmithKline plc., Abbott Laboratories Inc., AstraZeneca Plc., Medtronic Plc., Takeda Pharmaceutical Company Limited, Johnson And Johnson Services Inc., Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boston Scientific Corporation, Cadila Pharmaceuticals Ltd., Daewoong Pharmaceutical Co. Ltd, ANI Pharmaceuticals Inc., Dompe Farmaceutici S.p.A, Sucampo Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., RedHill Biopharma Ltd., CinRx Pharma LLC, Ritter Pharmaceuticals Inc., Evoke Pharma Inc., Metacrine Inc., and Neurogastrx Inc.

Collaborative Efforts Advancing Gastroparesis Therapies
In May 2025, German gastroenterology specialist Dr. Falk Pharma joined forces with U.S.-based biotech company Renexxion to accelerate the development and commercialization of innovative gastrointestinal treatments. This collaboration focuses on naronapride, a precision therapy designed to improve gastric motility in gastroparesis patients. Combining Dr. Falk Pharma's regulatory expertise with Renexxion's novel prokinetic technology, the partnership aims to bring this selective 5-HT4 agonist to market globally, enhancing treatment options for individuals with this condition.

View the full gastroparesis market report:
https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report?utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Highlighting New Possibilities in Gastroparesis Care
Pharmaceutical companies in the gastroparesis arena are actively working to expand their portfolios and drive growth through novel drug development. These drugs primarily target the symptoms related to delayed stomach emptying, offering relief to affected patients. A notable example occurred in December 2023 when Vanda Pharmaceuticals Inc., a U.S. biopharmaceutical firm, announced that the FDA accepted its New Drug Application for Tradipitant. This development marks a potentially significant breakthrough, as the FDA's Prescription Drug User Fee Act (PDUFA) decision is expected by September 18, 2024. If approved, Tradipitant would become the first new drug for gastroparesis to receive FDA clearance in over 40 years, representing a major milestone in treating this chronic condition.

Breakdown of Market Segments Defining Gastroparesis Treatment
The gastroparesis market is categorized into several distinct segments to better understand its diverse landscape. These include:
1) Treatment Modalities such as Medications, Dietary Modifications, Medical Devices, and Other Therapies.
2) Types of Gastroparesis, including Idiopathic, Diabetic, Post-Surgical, and other classifications.
3) Patient Demographics, separating Pediatric and Adult gastroparesis cases.
4) Distribution Channels, ranging from Retail and Hospital Pharmacies to other outlets.
5) End Users like Hospitals and Clinics, Ambulatory Surgical Centers, and Home Care Settings.

Within these broader categories, subsegments are defined as follows:
- Medications include Prokinetic Agents, Antiemetic Medications, and Pain Management Medications.
- Dietary Modifications cover Low-Fiber Diets, Small Frequent Meals, and Pureed or Liquid Diets.
- Medical Devices encompass Gastric Electrical Stimulation Devices and Enteral Feeding Tubes.
- Other Therapies involve Acupuncture, Behavioral Therapies, and Nutritional Supplements.

This detailed segmentation provides a comprehensive picture of the gastroparesis market, showcasing the multifaceted approaches being utilized to improve patient outcomes and expand treatment possibilities.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.